NeOnc Technologies Holdings shared an early clinical update on its investigational brain cancer treatment NEO100, highlighting a critically ill three-year-old boy with an aggressive brain tumor who showed improved breathing and movement after receiving the treatment through a compassionate-use program. This case underscores the urgent need for new therapies in difficult-to-treat brain cancers and the challenge of balancing compassionate use with rigorous clinical trials. NeOnc is advancing NEO100 through formal studies and regulatory approvals, including efforts in Abu Dhabi and the U.S., while also progressing a second drug candidate, NEO212. The company recently strengthened its board with a banking expert and completed a $15 million financing round to support ongoing development.
NeOnc Technologies' compassionate-use update on NEO100 offers context for readers interested in innovative health treatments. For readers following the health sector, here is Pluang's market snapshot as of Oct 16, 2026 19:42 WIB: of 150 priced US health stocks, 96 rose and 43 fell. Notable movers include NUWE at USD 0.58 with a 1-day change of +4.25% and a typical hold time of 27 days, FLNA at USD 0.73 down -3.76% with a 38-day hold, and HRTX at USD 0.39 up +3.05% with a 36-day hold. Pluang order activity shows mixed buy/sell interest across these stocks.
Opus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% for treating presbyopia, an age-related condition affecting near vision in adults. This approval, based on successful Phase 3 trials, provides a non-invasive option that i...
K2 Vision has completed over 5,000 procedures using the Light Adjustable Lens (LAL), making it the highest-volume practice worldwide for this technology. The LAL is unique because it can be adjusted after implantation to fine-tune vision based on the...
BlackRock, Inc. disclosed that its voting rights in pharmaceutical company Fagron NV fell below the 3% reporting threshold due to the transfer of voting securities, despite acquiring financial instruments equivalent to voting rights. As of October 12...
BlackRock, Inc. disclosed that its shareholding in Fagron NV dropped below the 3% threshold to 2.96% after selling some voting securities, despite acquiring equivalent financial instruments. As of October 12, 2026, BlackRock holds 2,015,779 voting ri...
Meridian International Center announced its inaugural New Architects of American Influence cohort, recognizing 25 leaders from business, technology, culture, sports, and government who are shaping U.S. global influence. The 2026 cohort includes leade...
